Ipamorelin vs MK-677
Ipamorelin and MK-677 (ibutamoren) are both growth hormone secretagogues (GHS) that stimulate GH release via the ghrelin receptor (GHSR1a), but they differ critically in receptor selectivity, cortisol co-secretion, oral bioavailability, and GH release patterns. These differences have significant implications for safety and therapeutic application.
Mechanism of Action
Section titled “Mechanism of Action”Ipamorelin
Section titled “Ipamorelin”Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts as a selective, peptidomimetic ghrelin receptor agonist. It binds GHSR1a with high affinity (EC₅₀ ~0.7 nM) and activates the Gq/PLC/IP₃/Ca²⁺ signaling cascade, stimulating GH release from somatotrophs.
The defining feature of ipamorelin is its selectivity: it activates GHSR1a without significantly stimulating cortisol, ACTH, prolactin, or aldosterone secretion. This selectivity is unique among GH secretagogues and makes ipamorelin the most pharmacologically refined GHS available.
Ipamorelin promotes pulsatile GH release that mimics physiological secretion patterns. The pulse amplitude increases while maintaining normal pulse frequency, producing a more physiological GH elevation than non-selective secretagogues.
MK-677 (Ibutamoren)
Section titled “MK-677 (Ibutamoren)”MK-677 is a non-peptide, benzylpiperazine-urea derivative that also binds GHSR1a but with a broader pharmacological profile. It activates GHSR1a with an EC₅₀ of ~1.3 nM and additionally stimulates:
- Cortisol secretion: Significant ACTH and cortisol elevation (dose-dependent)
- Aldosterone elevation: Via adrenal GHSR1a activation
- Prolactin: Modest increase
- IGF-1 elevation: Sustained rather than pulsatile
MK-677 produces sustained (non-pulsatile) GH elevation, with plasma GH remaining chronically elevated rather than exhibiting discrete pulses. This non-physiological pattern may have different downstream effects than pulsatile stimulation.
Comparison Table
Section titled “Comparison Table”| Property | Ipamorelin | MK-677 |
|---|---|---|
| Structure | Pentapeptide (peptidomimetic) | Non-peptide (benzylpiperazine) |
| Receptor selectivity | High (GHSR1a selective) | Low (GHSR1a + adrenal effects) |
| Cortisol elevation | Minimal (<10%) | Significant (30–50%) |
| ACTH elevation | Minimal | Significant |
| Prolactin elevation | Minimal | Mild |
| GH release pattern | Pulsatile | Sustained (non-pulsatile) |
| Half-life | ~2 hrs (IV), ~1 hr (SC) | ~1–2 hrs (oral) |
| Oral bioavailability | <5% (peptide) | ~60–70% (non-peptide) |
| Route | SC, IV | Oral |
Selectivity and Cortisol
Section titled “Selectivity and Cortisol”Ipamorelin Selectivity
Section titled “Ipamorelin Selectivity”Ipamorelin’s cortisol-neutral profile is its primary safety advantage. Studies demonstrate:
- Cortisol AUC change: <10% increase from baseline
- ACTH change: Not significantly different from placebo
- Aldosterone: No significant change
- Prolactin: No significant change
The selectivity is attributed to ipamorelin’s specific interaction with the GHSR1a transmembrane binding pocket, which differs from the broader GHSR1a conformational changes induced by ghrelin or non-selective secretagogues.
MK-677 Cortisol Effects
Section titled “MK-677 Cortisol Effects”MK-677 produces clinically significant cortisol elevation:
- Cortisol AUC increase: 30–50% in dose-ranging studies
- ACTH elevation: Parallel increase in plasma ACTH
- Dose-dependent: Greater cortisol elevation at higher doses (25 mg)
- Chronic exposure: Cortisol elevation persists with continued dosing
- Clinical concern: Long-term cortisol elevation may promote insulin resistance, visceral adiposity, and immunosuppression
This cortisol co-secretion is the primary safety concern limiting MK-677’s clinical utility and distinguishes it from ipamorelin pharmacologically.
GH Release Patterns
Section titled “GH Release Patterns”Ipamorelin: Pulsatile Release
Section titled “Ipamorelin: Pulsatile Release”Ipamorelin stimulates discrete GH pulses with:
- Pulse frequency: Maintained at physiological rate (6–8 pulses/24 hrs)
- Pulse amplitude: Increased 2–3-fold above baseline
- Peak GH levels: 15–25 ng/mL per pulse
- Inter-pulse troughs: Return toward baseline
- IGF-1 elevation: Moderate, sustained (15–25% above baseline)
The pulsatile pattern mimics physiological GH secretion during sleep, which is considered optimal for anabolic effects (muscle protein synthesis, lipolysis) while minimizing insulin resistance.
MK-677: Sustained Elevation
Section titled “MK-677: Sustained Elevation”MK-677 produces:
- GH plateau: Sustained elevation at 10–20 ng/mL for 8–12 hours
- No discrete pulses: Continuous GH exposure without inter-pulse troughs
- Peak GH levels: Lower per-exposure than ipamorelin pulses
- IGF-1 elevation: Higher sustained elevation (30–50% above baseline)
The non-physiological sustained pattern may produce different receptor desensitization kinetics and downstream signaling compared to pulsatile stimulation. Some evidence suggests sustained GH exposure is less anabolic and more diabetogenic than pulsatile exposure.
IGF-1 Elevation
Section titled “IGF-1 Elevation”| Parameter | Ipamorelin | MK-677 |
|---|---|---|
| Baseline IGF-1 | Reference | Reference |
| Peak IGF-1 increase | 15–25% | 30–50% |
| Duration of elevation | 12–24 hrs | 24–48 hrs |
| Steady state (chronic dosing) | Moderate elevation | Higher elevation |
| Feedback suppression | Minimal | Some GH receptor downregulation |
MK-677 achieves higher absolute IGF-1 levels, but the clinical significance of this difference is uncertain. The sustained elevation may produce greater GH receptor downregulation over time, potentially attenuating long-term efficacy.
Dosing and Administration
Section titled “Dosing and Administration”Ipamorelin
Section titled “Ipamorelin”| Route | Dose | Frequency | Bioavailability |
|---|---|---|---|
| Subcutaneous | 200–300 µg | 2–3x daily | ~60–70% |
| Intravenous | 100–200 µg | 1–2x daily | 100% |
Ipamorelin’s short half-life (~2 hrs) requires multiple daily injections or continuous infusion for sustained effect. The short half-life is also advantageous for cycling protocols.
MK-677
Section titled “MK-677”| Route | Dose | Frequency | Bioavailability |
|---|---|---|---|
| Oral | 10–25 mg | Once daily | ~60–70% |
MK-677’s oral bioavailability is a significant practical advantage. Once-daily dosing with no injection requirement improves adherence. However, the cortisol elevation at effective doses limits its clinical use.
Safety Profile
Section titled “Safety Profile”Ipamorelin
Section titled “Ipamorelin”- Well-tolerated in clinical trials
- No clinically significant cortisol elevation
- No hypoglycemia at therapeutic doses
- No significant GI effects
- Injection site reactions (mild, self-limited)
- Theoretical concern: long-term GH elevation effects unknown
MK-677
Section titled “MK-677”- Cortisol elevation: Primary safety concern (30–50% increase)
- Insulin resistance: Worsened glucose tolerance in some studies
- Increased appetite: Dose-dependent
- Fluid retention: Peripheral edema reported
- Paresthesias: Tingling/numbness in extremities
- Lethargy: Drowsiness, particularly at higher doses
- Cardiac effects: Potential for cardiac hypertrophy with chronic use (theoretical)
When to Choose Which
Section titled “When to Choose Which”Ipamorelin may be preferred when:
- Cortisol-neutral GH stimulation is required
- Pulsatile GH release pattern is desired
- Safety profile is paramount
- Injection is acceptable
- Short-term or cycling use is planned
MK-677 may be considered when:
- Oral administration is required
- Cost or accessibility favors oral formulations
- Higher IGF-1 elevation is the goal
- Clinical context accepts cortisol elevation risk
- Short-term use with monitoring
References
Section titled “References”- Andersen AN, et al. “Growth hormone release from the new hexapeptide, ipamorelin.” J Clin Endocrinol Metab 1995;80:2416-2421.
- Chapman IM, et al. “Growth hormone secretagogue efficacy and effects on cortisol.” J Clin Endocrinol Metab 1997;82:1948-1955.
- Smith RG, et al. “MK-677, a novel growth hormone secretagogue.” Science 1993;260:164-166.
- Nass R, et al. “Effects of an oral ghrelin secretagogue on body composition.” J Clin Endocrinol Metab 2008;93:715-722.
- Johansen PB, et al. “Ipamorelin: a novel growth hormone secretagogue.” Eur J Endocrinol 2000;143:575-580.